Lineage Cell Therapeutics, Inc.: shareholders and insiders

LCTXAMEXHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.77

November 20, 2026Market cap $192M

What Ploutos Investor adds for Lineage Cell Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($0.99 then, $0.77 on Nov 20, 2026). The figures date from before that move.10-Q
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 19, 2026, from their own Form 4 filings.

11 Form 4s

Bought on the market

$895.4K

5 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $895.4K by 5 people·no sales

  • 2025: no buys, no sales
  • 2026: bought $895.4K by 5 people, no sales
  • Nov 17, 2026Broadwood Partners, L.p.Director
    Kind
  • Nov 17, 2026Broadwood Partners, L.p.Director
    Kind
  • Nov 17, 2026Michael H. MulroyDirector
    Kind
  • Nov 16, 2026Deborah J AndrewsDirector
    Kind
  • Nov 16, 2026Brian M CulleyPresident and CEO
    Kind
  • Nov 16, 2026Jill Ann HoweChief Financial Officer
    Kind
  • Mar 12, 2026Brian M CulleyPresident and CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jul 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by LCTX's officers and directors from 2006 up to November 21, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%1 On a 13DJul 29, 2026 Latest filing
  • Broadwood Partnerswith 2 more personsCommon shares
    Share of class23.1%
  • BlackRock, Inc.
    Share of class5.30%
  • Chernett JoreyCommon
    Share of class5.00%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Broadwood Partners23.1%From the filing of Nov 14, 2025

    The Reporting Persons acquired their Shares for investment and are filing this Schedule 13D/A to report a decrease in their respective beneficial ownership percentages of the Shares as a result of the sale of 12,000,000 Shares by the Issuer to Janus Henderson Investors in a block transaction under the Issuer's at-the-market offering program as described in the Form 8-K filed with the Securities and Exchange Commission by the Issuer on November 12, 2025 (the "Form 8-K"). The foregoing is a summary of certain material terms of the Form 8-K. However, such summary is not, and does not purport to be, complete and is qualified in its entirety by reference to the full text of the Form 8-K, which…

    From the filing of Nov 14, 2025

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter-20%
  • Millennium Mgmt (Englander)
    In the quarter-13%
  • Renaissance Technologies
    In the quarter-50%
  • AQR Capital
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 10.4% of its shares outstanding were held short, -10.9% since the report before.

Shares held short
25.93M
10.4%
Since the report before29.09M on Sep 30, 2026
-10.9%
16.8
1.55M
More days to cover thanof 4,578 US-listed companies with enough volume
99%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 6.15M
  • Nov 15, 2023: Shares held short 6.01M
  • Nov 30, 2023: Shares held short 6.37M
  • Dec 15, 2023: Shares held short 6.15M
  • Dec 29, 2023: Shares held short 6.94M
  • Jan 12, 2024: Shares held short 7.88M
  • Jan 31, 2024: Shares held short 8.46M
  • Feb 15, 2024: Shares held short 10.04M
  • Feb 29, 2024: Shares held short 9.62M
  • Mar 15, 2024: Shares held short 9.98M
  • Mar 28, 2024: Shares held short 10.40M
  • Apr 15, 2024: Shares held short 10.58M
  • Apr 30, 2024: Shares held short 10.90M
  • May 15, 2024: Shares held short 12.37M
  • May 31, 2024: Shares held short 12.26M
  • Jun 14, 2024: Shares held short 12.92M
  • Jun 28, 2024: Shares held short 12.92M
  • Jul 15, 2024: Shares held short 14.56M
  • Jul 31, 2024: Shares held short 14.56M
  • Aug 15, 2024: Shares held short 15.51M
  • Aug 30, 2024: Shares held short 15.82M
  • Sep 13, 2024: Shares held short 15.63M
  • Sep 30, 2024: Shares held short 15.22M
  • Oct 15, 2024: Shares held short 15.77M
  • Oct 31, 2024: Shares held short 15.94M
  • Nov 15, 2024: Shares held short 16.13M
  • Nov 29, 2024: Shares held short 18.34M
  • Dec 13, 2024: Shares held short 22.94M
  • Dec 31, 2024: Shares held short 26.03M
  • Jan 15, 2025: Shares held short 27.11M
  • Jan 31, 2025: Shares held short 21.30M
  • Feb 14, 2025: Shares held short 21.55M
  • Feb 28, 2025: Shares held short 22.03M
  • Mar 14, 2025: Shares held short 22.34M
  • Mar 31, 2025: Shares held short 26.64M
  • Apr 15, 2025: Shares held short 28.43M
  • Apr 30, 2025: Shares held short 30.00M
  • May 15, 2025: Shares held short 29.96M
  • May 30, 2025: Shares held short 29.41M
  • Jun 13, 2025: Shares held short 28.73M
  • Jun 30, 2025: Shares held short 27.74M
  • Jul 15, 2025: Shares held short 28.09M
  • Jul 31, 2025: Shares held short 27.24M
  • Aug 15, 2025: Shares held short 26.76M
  • Aug 29, 2025: Shares held short 27.05M
  • Sep 15, 2025: Shares held short 27.75M
  • Sep 30, 2025: Shares held short 29.01M
  • Oct 15, 2025: Shares held short 31.77M
  • Oct 31, 2025: Shares held short 33.80M
  • Nov 14, 2025: Shares held short 22.58M
  • Nov 28, 2025: Shares held short 22.84M
  • Dec 15, 2025: Shares held short 23.71M
  • Dec 31, 2025: Shares held short 24.64M
  • Jan 15, 2026: Shares held short 25.10M
  • Jan 30, 2026: Shares held short 25.35M
  • Feb 13, 2026: Shares held short 25.19M
  • Feb 27, 2026: Shares held short 25.05M
  • Mar 13, 2026: Shares held short 25.47M
  • Mar 31, 2026: Shares held short 25.47M
  • Apr 15, 2026: Shares held short 25.29M
  • Apr 30, 2026: Shares held short 25.58M
  • May 15, 2026: Shares held short 25.92M
  • May 29, 2026: Shares held short 26.08M
  • Jun 15, 2026: Shares held short 25.56M
  • Jun 30, 2026: Shares held short 28.19M
  • Jul 15, 2026: Shares held short 29.87M
  • Jul 31, 2026: Shares held short 29.56M
  • Aug 14, 2026: Shares held short 28.33M
  • Aug 31, 2026: Shares held short 28.98M
  • Sep 15, 2026: Shares held short 29.47M
  • Sep 30, 2026: Shares held short 29.09M
  • Oct 15, 2026: Shares held short 25.93M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading51.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 51.1% of the shares in the reported trades were short sales, against 69.1% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
51.1%
The 14 beforeOct 14, 2026 – Nov 2, 2026
69.1%
Change
-18.0 pts
Short sales a dayon average, of 898.5K shares
459.3K
More than atof 3,666 US-listed companies, same days
52%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 62.1%
  • Oct 15, 2026: Short sales 64%
  • Oct 16, 2026: Short sales 74.3%
  • Oct 19, 2026: Short sales 76.9%
  • Oct 20, 2026: Short sales 66.6%
  • Oct 21, 2026: Short sales 74.8%
  • Oct 22, 2026: Short sales 73.4%
  • Oct 23, 2026: Short sales 78.2%
  • Oct 26, 2026: Short sales 78.6%
  • Oct 27, 2026: Short sales 48.8%
  • Oct 28, 2026: Short sales 72.7%
  • Oct 29, 2026: Short sales 65.9%
  • Oct 30, 2026: Short sales 72.6%
  • Nov 2, 2026: Short sales 62.2%
  • Nov 3, 2026: Short sales 66.7%
  • Nov 4, 2026: Short sales 50%
  • Nov 5, 2026: Short sales 54.8%
  • Nov 6, 2026: Short sales 56.5%
  • Nov 9, 2026: Short sales 45.9%
  • Nov 10, 2026: Short sales 74.4%
  • Nov 11, 2026: Short sales 50.2%
  • Nov 12, 2026: Short sales 59.4%
  • Nov 13, 2026: Short sales 70.5%
  • Nov 16, 2026: Short sales 42.1%
  • Nov 17, 2026: Short sales 36.6%
  • Nov 18, 2026: Short sales 53.8%
  • Nov 19, 2026: Short sales 50.9%
  • Nov 20, 2026: Short sales 42.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

201M Insiders' shares80.79% Of the company
  • Broadwood Partners, L.p.Director,TenPercentOwner
    Directly59.54M
  • Broadwood Capital IncTenPercentOwner
    Directly49.56M
  • Michael H. MulroyDirector
    Directly328.6K
  • Brian M CulleyPresident and CEO
    Directly296.0K
  • Don M BaileyDirector
    Directly–
  • Jill Ann HoweChief Financial Officer
    Directly45.5K
  • Deborah J AndrewsDirector
    Directly40.6K
  • George A. Samuel IIIGeneral Counsel
    Directly22.2K
  • Anula JayasuriyaDirector
    Directly10.0K

A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

7 ETFs holding it0.05% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.05%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.02%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

7 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

131 Managers, Q2 2026$153M Value of their positions
  • Q3 2025: Managers 113
  • Q4 2025: Managers 123
  • Q1 2026: Managers 131
  • Q2 2026: Managers 131

Institutional investors by quarter

The fund managers holding LCTX, quarter by quarter, from Q2 2019 to Q2 2025, 25 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 131 managers held 117M shares, worth $153M. During the quarter 34 opened a position, 35 closed one, 24 added and 30 trimmed.

The largest holders, Q2 2026

  • Broadwood Capital
    In the quarter
  • BlackRock
    In the quarter+241%
  • Vanguard Capital Management
    In the quarter+8.9%
  • Defender Capital
    In the quarter-1.9%
  • Geode Capital Management
    In the quarter+110%
  • Raffles Associates
    In the quarter-3.1%
  • Fifth Third Bancorp
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-46%
  • State Street
    In the quarter+112%
  • Vanguard Fiduciary Trust
    In the quarter+26%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Lineage Cell Therapeutics's filings show?

Who buys and sells is one part of Lineage Cell Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LCTX's shareholders

Didn't find what you were looking for?

Ask us
Have LCTX's insiders bought or sold?

From Jul 2, 2026 to Nov 19, 2026 Lineage Cell Therapeutics's insiders bought $871.0K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold LCTX?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $2.5M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.